Table 3 Baseline characteristics before and after propensity score matching
Clinical parameters | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
PGC (n = 44) | GC (n = 415) | P value | PGC (n = 44) | GC (n = 44) | P value | |
Age (years ≥ 70) | 29.5% (13/44) | 28.2% (117/415) | 0.850 | 29.5% (13/44) | 27.3% (12/44) | 0.813 |
Gender ( Male) | 75.0% (33/44) | 70.4% (292/415) | 0.520 | 75.0% (33/44) | 70.5% (31/44) | 0.632 |
Tumor diameter (≥ 5 cm) | 72.7% (32/44) | 41.2% (171/415) |  < 0.001 | 72.7% (32/44) | 82.8% (36/44) | 0.309 |
Tumor differentiation ( SRCC or Poorly) | 88.6% (39/44) | 68.4% (284/415) | 0.005 | 88.6%(39/44) | 86.4% (38/44) | 0.747 |
T staging (T4) | 97.7% (43/44) | 32.1% (133/415) |  < 0.001 | 97.7%(43/44) | 97.7% (43/44) |  > 0.999 |
N staging (N positive) | 84.1% (37/44) | 58.8% (244/415) | 0.001 | 84.1%(37/44) | 86.4% (38/44) | 0.764 |
M staging (M positive) | 0.0% (0/44) | 1.7% (7/415) | 0.385 | 0.0% (0/44) | 0.0% (0/44) |  > 0.999 |
Location (Lower 1/3) | 81.8% (36/44) | 61.7% (256/415) | 0.008 | 81.8% (36/44) | 75.0% (33/44) | 0.437 |
CEA (≥ 10 ng/mL) | 18.2% (8/44) | 8.7% (40/415) | 0.078 | 18.2% (8/44) | 22.7% (10/44) | 0.921 |
Neoadjuvant chemotherapy (YES) | 13.6% (6/44) | 4.6% (19/415) | 0.012 | 13.6% (6/44) | 18.2% (8/44) | 0.560 |
Adjuvant chemotherapy (YES) | 100.0% (44/44) | 63.6% (264/415) |  < 0.001a | 100.0% (44/44) | 100% (44/44) |  > 0.999a |